MY197630A - Solvate form of (r)-2-amino-3-phenylpropyl carbamate - Google Patents

Solvate form of (r)-2-amino-3-phenylpropyl carbamate

Info

Publication number
MY197630A
MY197630A MYPI2019001180A MYPI2019001180A MY197630A MY 197630 A MY197630 A MY 197630A MY PI2019001180 A MYPI2019001180 A MY PI2019001180A MY PI2019001180 A MYPI2019001180 A MY PI2019001180A MY 197630 A MY197630 A MY 197630A
Authority
MY
Malaysia
Prior art keywords
amino
solvate form
hydrochloride
phenylpropyl carbamate
apc
Prior art date
Application number
MYPI2019001180A
Other languages
English (en)
Inventor
Leigh Nelson Jennifer
Hurley Fionn
Original Assignee
Sk Biopharmaceuticals Co Ltd
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61562003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY197630(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sk Biopharmaceuticals Co Ltd, Jazz Pharmaceuticals Ireland Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MY197630A publication Critical patent/MY197630A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/08Separation; Purification; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
MYPI2019001180A 2016-09-06 2017-09-06 Solvate form of (r)-2-amino-3-phenylpropyl carbamate MY197630A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662383822P 2016-09-06 2016-09-06
PCT/US2017/050233 WO2018048871A1 (en) 2016-09-06 2017-09-06 Solvate form of (r)-2-amino-3-phenylpropyl carbamate

Publications (1)

Publication Number Publication Date
MY197630A true MY197630A (en) 2023-06-29

Family

ID=61562003

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019001180A MY197630A (en) 2016-09-06 2017-09-06 Solvate form of (r)-2-amino-3-phenylpropyl carbamate

Country Status (13)

Country Link
US (4) US10829443B2 (https=)
EP (2) EP3509582B1 (https=)
JP (3) JP7219213B2 (https=)
KR (1) KR102513800B1 (https=)
CN (4) CN109996540A (https=)
CA (1) CA3036071A1 (https=)
DK (1) DK3509582T3 (https=)
ES (1) ES2970887T3 (https=)
FI (1) FI3509582T3 (https=)
MY (1) MY197630A (https=)
PH (1) PH12019500493A1 (https=)
SG (1) SG11201901998WA (https=)
WO (1) WO2018048871A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
MY197630A (en) 2016-09-06 2023-06-29 Sk Biopharmaceuticals Co Ltd Solvate form of (r)-2-amino-3-phenylpropyl carbamate
WO2020035769A1 (en) 2018-08-14 2020-02-20 Glenmark Pharmaceuticals Limited; Glenmark Life Sciences Limited Process for the preparation of solriamfetol and salt thereof
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
WO2021001457A1 (en) 2019-07-04 2021-01-07 Sandoz Ag Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts
IT202000013855A1 (it) 2020-06-10 2021-12-10 Flamma Spa Un processo per la purificazione del (r)-2-ammino-3-fenilpropil carbammato
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
AU2023375326A1 (en) * 2022-11-07 2025-05-22 Axsome Therapeutics Compositions and methods for treating insomnia
WO2024145545A2 (en) * 2022-12-30 2024-07-04 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
WO2024194718A1 (en) 2023-03-22 2024-09-26 Unichem Laboratories Limited A stable pharmaceutical composition and process for preparing thereof
CN121816178A (zh) 2023-05-30 2026-04-07 艾克萨姆治疗股份有限公司 用于治疗患有与阻塞性睡眠呼吸暂停和白天过度嗜睡相关的认知受损的受试者的认知受损的索安非托
KR20260033050A (ko) 2023-06-29 2026-03-10 액섬 테라퓨틱스, 인크. 수유 여성에게 솔리암페톨을 투여하는 방법
WO2025042959A1 (en) 2023-08-21 2025-02-27 Axsome Therapeutics, Inc. Use of solriamfetol for the treatment of orphan diseases
WO2025165760A1 (en) * 2024-01-29 2025-08-07 Axsome Therapeutics, Inc. Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
DK1140061T3 (da) 1998-12-23 2003-08-25 Orphan Medical Inc Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi
RU2202607C2 (ru) 2000-03-03 2003-04-20 Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" Штамм бактерий methylophilus methylotrophus - продуцент l-фенилаланина (варианты), способ получения l-фенилаланина
US20050080268A1 (en) * 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
RU2007119648A (ru) 2004-10-28 2008-12-10 СК Холдингз Ко. Способ лечения депрессии
EP1890684B1 (en) * 2005-06-08 2013-08-14 SK Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
ES2344469T3 (es) * 2005-06-22 2010-08-27 Sk Holdings Co., Ltd. Tratamiento de disfuncion sexual.
KR20120098578A (ko) 2009-06-22 2012-09-05 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
BR112012010670A2 (pt) 2009-11-06 2016-04-12 Sk Biopharmaceuticals Co Ltd métodos para tratamento de distúrbio de défict de atenção/hiperatividade
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
CA2905457A1 (en) 2013-03-13 2014-10-09 Aerial Biopharma, Llc Treatment of cataplexy
JP2016530240A (ja) 2013-07-12 2016-09-29 ジャズ ファーマスティカルズ インターナショナル スリー リミテッドJazz Pharmaceuticals International Iii Limited 禁煙の促進
CA2917702A1 (en) 2013-07-18 2015-01-22 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
JP2019512009A (ja) 2016-02-16 2019-05-09 ザ・ユニバーシティ・オブ・クイーンズランド スルホニルウレアおよび関連化合物ならびにこれらの利用
MY197630A (en) * 2016-09-06 2023-06-29 Sk Biopharmaceuticals Co Ltd Solvate form of (r)-2-amino-3-phenylpropyl carbamate
KR101950254B1 (ko) 2016-09-21 2019-02-20 유상신 차량탑승자의 부재를 감지하는 지능형 카시트
WO2020035769A1 (en) * 2018-08-14 2020-02-20 Glenmark Pharmaceuticals Limited; Glenmark Life Sciences Limited Process for the preparation of solriamfetol and salt thereof

Also Published As

Publication number Publication date
CN120574152A (zh) 2025-09-02
SG11201901998WA (en) 2019-04-29
JP7219213B2 (ja) 2023-02-07
EP3509582A1 (en) 2019-07-17
JP7642506B2 (ja) 2025-03-10
CA3036071A1 (en) 2018-03-15
US20250340509A1 (en) 2025-11-06
EP3509582A4 (en) 2020-05-13
US12384743B2 (en) 2025-08-12
EP4364794A2 (en) 2024-05-08
US20230183172A1 (en) 2023-06-15
US10829443B2 (en) 2020-11-10
DK3509582T3 (en) 2024-02-12
WO2018048871A1 (en) 2018-03-15
FI3509582T3 (fi) 2024-02-08
KR20190065311A (ko) 2019-06-11
US20210053912A1 (en) 2021-02-25
JP2022003062A (ja) 2022-01-11
JP2024178291A (ja) 2024-12-24
CN121202730A (zh) 2025-12-26
US20190194126A1 (en) 2019-06-27
CN109996540A (zh) 2019-07-09
EP4364794A3 (en) 2024-07-24
CN121202731A (zh) 2025-12-26
JP2019535643A (ja) 2019-12-12
EP3509582B1 (en) 2023-12-20
PH12019500493A1 (en) 2019-05-27
ES2970887T3 (es) 2024-05-31
US11560354B2 (en) 2023-01-24
KR102513800B1 (ko) 2023-03-24

Similar Documents

Publication Publication Date Title
PH12019500493A1 (en) Solvate form of (r)-2-amino-3-phenylpropyl carbamate
MY195408A (en) Novel Aspartokinase Variant and Method for Producing L- Amino Acid Using the Same
SG11202010603TA (en) Method for producing acrylic rubber, and acrylic rubber obtained by said production method
EP4585268A3 (en) Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
GEP20196974B (en) A novel crystalline form of a benzimidazole derivative and a preparation method thereof
MX2019011759A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando el mismo.
MX2019011758A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
UA122483C2 (uk) Підслідники і спосіб їх виготовлення
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
ZA201707152B (en) Methods for hydraulic enhancement of crops
MX2019011730A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
ZA202101833B (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants
AU2017257755A1 (en) Benzoylglycine derivatives and methods of making and using same
WO2018093223A3 (ko) 엘더칼시톨의 제조방법 및 그를 위한 중간체
GB2566229A (en) Club heads having reinforced club head faces and related methods
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
AU364584S (en) Wooden arc hammock frame
DK3592723T3 (da) Fremgangsmåde til fremstilling af 3,3,3-trifluorprop-1-en
PH12020550834A1 (en) Fermented soybean composition and method for producing fermented soybean composition
SG11202012127YA (en) Acellular organs, and methods of producing the same
PH12018502350A1 (en) Method for the production of molded bodies for administration to animals
IL289971A (en) Improved methods for the production of plants
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
GB201814291D0 (en) Process for the production of gallium radionculides
PH12017501869A1 (en) (s)-2'-vinyl-abscisic acid derivatives